MUSURACA, GERARDO
 Distribuzione geografica
Continente #
AS - Asia 1.356
NA - Nord America 1.057
EU - Europa 736
SA - Sud America 68
AF - Africa 67
OC - Oceania 3
Totale 3.287
Nazione #
US - Stati Uniti d'America 1.038
VN - Vietnam 457
SG - Singapore 301
CN - Cina 298
IT - Italia 148
GB - Regno Unito 143
SE - Svezia 111
HK - Hong Kong 101
DE - Germania 94
IN - India 51
BR - Brasile 48
FR - Francia 48
RU - Federazione Russa 34
NL - Olanda 33
IE - Irlanda 30
JP - Giappone 28
TG - Togo 25
KR - Corea 21
FI - Finlandia 20
JO - Giordania 16
CI - Costa d'Avorio 14
CA - Canada 10
ZA - Sudafrica 10
BG - Bulgaria 9
EE - Estonia 9
ID - Indonesia 9
PH - Filippine 9
CH - Svizzera 8
IQ - Iraq 8
TH - Thailandia 8
NG - Nigeria 7
TR - Turchia 7
AR - Argentina 6
AT - Austria 6
BD - Bangladesh 6
EC - Ecuador 6
ES - Italia 6
HR - Croazia 6
MX - Messico 6
PK - Pakistan 6
UA - Ucraina 6
BE - Belgio 5
PL - Polonia 5
MY - Malesia 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
IR - Iran 3
LB - Libano 3
SA - Arabia Saudita 3
TW - Taiwan 3
AU - Australia 2
DK - Danimarca 2
GR - Grecia 2
IL - Israele 2
LT - Lituania 2
PS - Palestinian Territory 2
QA - Qatar 2
SC - Seychelles 2
UZ - Uzbekistan 2
AL - Albania 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CG - Congo 1
CO - Colombia 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
GH - Ghana 1
GY - Guiana 1
HT - Haiti 1
HU - Ungheria 1
KE - Kenya 1
KH - Cambogia 1
LV - Lettonia 1
MA - Marocco 1
MC - Monaco 1
MD - Moldavia 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SI - Slovenia 1
SO - Somalia 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 3.287
Città #
Singapore 206
Ashburn 141
Southend 116
Ho Chi Minh City 115
Hong Kong 92
Hanoi 82
San Jose 69
Fairfield 68
Hefei 61
Chandler 59
Santa Clara 48
Houston 47
Seattle 45
Woodbridge 45
Beijing 41
New York 41
Dong Ket 39
Ann Arbor 32
Los Angeles 32
Boardman 30
Dublin 30
Princeton 30
Cambridge 25
Lomé 25
Lauterbourg 23
Wilmington 23
Tokyo 20
Turin 20
Bologna 19
Seoul 19
Amman 16
Helsinki 15
Abidjan 14
Da Nang 14
Haiphong 14
Nanjing 14
Munich 13
Council Bluffs 12
Frankfurt am Main 11
Berlin 10
Westminster 10
Dallas 9
Bern 8
Padova 8
Abeokuta 7
Bengaluru 7
Bremen 7
Changsha 7
Chicago 7
London 7
Sofia 7
Guangzhou 6
Hải Dương 6
Jakarta 6
Salsomaggiore Terme 6
Brussels 5
Izumo 5
Jiaxing 5
Jinan 5
Medford 5
Milan 5
Modena 5
Redwood City 5
San Diego 5
Shenyang 5
Wuhan 5
Amsterdam 4
Baghdad 4
Buffalo 4
Can Tho 4
Chengdu 4
Falkenstein 4
Florence 4
Hangzhou 4
Nanchang 4
Nha Trang 4
Nuremberg 4
Quito 4
Redondo Beach 4
Rome 4
Saint Petersburg 4
Shanghai 4
Shijiazhuang 4
Warsaw 4
Bangkok 3
Buenos Aires 3
Bình Phước 3
Bắc Giang 3
Chennai 3
Des Moines 3
Forlì 3
Hyderabad 3
Mumbai 3
Ninh Bình 3
Ottawa 3
Quận Ninh Kiều 3
Salvador 3
San Francisco 3
São Paulo 3
Thái Nguyên 3
Totale 2.059
Nome #
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 232
A phase 2 trial of fludarabine and mitoxantrone chemoterapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma 232
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 199
Patologic IL 17 Producing Helper T Cells In Acute Myeloid Leukemia Patients 195
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 173
Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. 171
The emerging role of GSK-3β in the pathobiology of classical Hodgkin lymphoma 170
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 169
Can early switch to rituximab-bendamustine in a patient with follicular non-Hodgkin lymphoma progressing during R-CHOP be considered frontline treatment?: A case report 163
Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: Multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials 161
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 160
Combining Gene Expression Profiling and Integrated Multidisciplinary Approaches to Improve Prognosis Prediction in Multiple Myeloma 156
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML 153
Genomic-Wide Analysis By High Resolution SNP Array Identifies Novel Genomic Alteration in Acute Myeloid Leukemia 149
Chimeric Antigen Receptor T-Cell Therapy: What We Expect Soon 136
Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin 131
Unexpected low expression of platelet fibrinogen receptor in patients with chronic myeloproliferative neoplasms: how does it change with aspirin? 131
Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells 124
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 89
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 81
Lenalidomide plus rituximab for the initial treatment of elderly frail patients with DLBCL: the FIL_ReRi Phase 2 Study 74
The safety profile of FLT3 inhibitors in the treatment of newly diagnosed or relapsed/refractory acute myeloid leukemia 53
Integrated multidisciplinary approaches to improve prognosis prediction in multiple myeloma 44
Totale 3.346
Categoria #
all - tutte 8.915
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.915


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021101 0 0 0 0 0 0 0 0 0 12 12 77
2021/2022294 42 5 17 31 24 13 4 19 19 23 58 39
2022/2023368 39 55 15 44 21 21 9 14 68 17 35 30
2023/2024139 11 22 7 13 7 49 4 4 7 5 2 8
2024/2025555 23 85 48 40 73 24 44 17 20 51 27 103
2025/20261.375 132 185 108 122 123 53 133 50 380 89 0 0
Totale 3.346